MOTS-C is a 16-amino acid peptide encoded by the mitochondrial genome — making it a "mitochondrial-derived peptide" (MDP). It was discovered in 2015 at the USC Leonard Davis School of Gerontology and represents a paradigm shift in how we understand mitochondrial signaling.
MOTS-C activates the AMPK (AMP-activated protein kinase) pathway — the same metabolic master switch activated by exercise and caloric restriction. AMPK activation triggers a cascade of metabolic benefits: increased glucose uptake, enhanced fatty acid oxidation, improved insulin sensitivity, and suppression of inflammatory pathways.
The peptide is sometimes called an "exercise mimetic" because it produces many of the same metabolic effects as exercise at the cellular level. It improves mitochondrial function, enhances cellular energy production, and protects against metabolic stress.
MOTS-C levels decline naturally with age and in metabolic disease states (obesity, type 2 diabetes), which has led to investigation of its role in age-related metabolic decline. It translocates from mitochondria to the nucleus during metabolic stress, directly regulating gene expression related to glucose metabolism and antioxidant defense.
MOTS-C is a relatively recently discovered peptide with a rapidly growing research base.
Obesity & Metabolism: In diet-induced obese mice, MOTS-C administration prevented weight gain, improved insulin sensitivity, and increased fatty acid oxidation. These effects occurred even without changes in food intake — suggesting a direct metabolic effect rather than appetite suppression.
Exercise Mimetic: Research demonstrated that MOTS-C treatment improved exercise performance in mice, including increased endurance capacity. The metabolic improvements mirrored those seen with regular exercise, earning it the "exercise in a bottle" description.
Aging & Longevity: Circulating MOTS-C levels decline with age across species. Supplementation in aged mice improved physical performance and metabolic parameters. This age-related decline parallels many features of metabolic aging.
Insulin Sensitivity: MOTS-C improved glucose tolerance and insulin sensitivity in both normal and metabolically challenged models, suggesting potential applications in prediabetes and type 2 diabetes management.
Inflammation: MOTS-C has demonstrated anti-inflammatory effects through AMPK-mediated inhibition of NF-κB signaling, adding an anti-inflammatory dimension to its metabolic benefits.
PCOS: Emerging research suggests MOTS-C levels may be altered in polycystic ovary syndrome (PCOS), with supplementation potentially improving metabolic parameters associated with the condition.
The following protocols are reported from clinical practice. This is not medical advice. Consult a licensed healthcare provider before starting any peptide therapy.
MOTS-C is administered via subcutaneous injection. Reported clinical approaches include:
Standard Metabolic Protocol: 5–10 mg subcutaneously, 2–3 times per week. Some providers use daily dosing at lower amounts (5 mg/day).
Weight Management: 10 mg subcutaneously, 3 times per week, combined with exercise and dietary modifications. MOTS-C is positioned as a complement to lifestyle changes, not a replacement.
Longevity Protocol: 5 mg subcutaneously, 2–3 times per week. Often stacked with Epitalon, GHK-Cu, and NAD+ in comprehensive anti-aging regimens.
Common Stacks: MOTS-C + AOD-9604 for metabolic optimization, MOTS-C + NAD+ for mitochondrial support, MOTS-C + Epitalon for comprehensive longevity.
Cycle Length: 8–12 weeks on, 4 weeks off. Some longevity-focused providers run longer cycles with periodic metabolic lab monitoring.
MOTS-C is an endogenously produced peptide (your body naturally makes it), contributing to its favorable safety profile. Commonly reported effects include mild injection site reactions, occasional temporary decrease in blood sugar (consistent with improved insulin sensitivity — those on diabetes medications should monitor closely), and mild muscle soreness similar to post-exercise effects.
No serious adverse events have been reported in the published literature. However, the peptide is relatively new (discovered 2015), and long-term safety data in humans is still being accumulated. Individuals on diabetes medications should work closely with their provider due to MOTS-C's glucose-lowering effects.
Verified suppliers with third-party testing and COA documentation. Use code POWER where applicable.
No. While MOTS-C activates many of the same metabolic pathways as exercise (AMPK activation, improved insulin sensitivity, enhanced fatty acid oxidation), exercise provides additional benefits including cardiovascular conditioning, musculoskeletal loading, and psychological effects that a peptide cannot replicate. MOTS-C is best viewed as a supplement to exercise, not a replacement.
MOTS-C improves metabolic function (fat oxidation, insulin sensitivity, glucose utilization) which can support weight management when combined with appropriate diet and exercise. It is not a direct appetite suppressant like GLP-1 agonists. Its metabolic benefits are more subtle and long-term.
AOD-9604 directly stimulates lipolysis (fat breakdown) through beta-3 adrenergic receptor activation. MOTS-C works at a more fundamental level by improving overall mitochondrial function and cellular energy metabolism. They target different pathways and can be stacked for complementary effects.
MOTS-C is one of only a handful of known mitochondrial-derived peptides — encoded by mitochondrial DNA rather than nuclear DNA. This mitochondrial origin is significant because it means MOTS-C is part of the organelle-level signaling system that directly controls cellular energy production and metabolic regulation.
Take our 2-minute quiz to get a personalized peptide recommendation based on your goals, experience level, and health priorities.
Take the Peptide Quiz →This content is for informational and educational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, cure, or prevent any disease or condition. Always consult with a qualified healthcare provider before starting any peptide therapy or supplement regimen. Peptide protocols described on this page reflect reported clinical practices and published research — not recommendations. Individual results may vary. Read full disclaimer.
Affiliate Disclosure: PeptideOnline.co participates in affiliate programs with suppliers featured on this page. We may earn a commission on qualifying purchases at no additional cost to you. Our editorial content is independent and not influenced by affiliate relationships. Learn more.